Leishmaniavirus genetic diversity is not related to leishmaniasis treatment failure
The outcome of American tegumentary leishmaniasis (ATL) may depend on the presence of the Leishmania RNA virus (LRV). This virus may be involved in treatment failure. We aimed to determine whether genetic clusters of LRV1 are involved in this therapeutic outcome. The presence of LRV1 was assessed in...
Gespeichert in:
| Veröffentlicht in: | Clinical microbiology and infection 2021-02, Vol.27 (2), p.286.e1-286.e5 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 286.e5 |
|---|---|
| container_issue | 2 |
| container_start_page | 286.e1 |
| container_title | Clinical microbiology and infection |
| container_volume | 27 |
| creator | Ginouvès, M. Couppié, P. Simon, S. Bourreau, E. Rogier, S. Brousse, P. Travers, P. Pommier de Santi, V. Demar, M. Briolant, S. Prévot, G. |
| description | The outcome of American tegumentary leishmaniasis (ATL) may depend on the presence of the Leishmania RNA virus (LRV). This virus may be involved in treatment failure. We aimed to determine whether genetic clusters of LRV1 are involved in this therapeutic outcome.
The presence of LRV1 was assessed in 129 Leishmania guyanensis isolates from patients treated with pentamidine in French Guiana. Among the 115 (89%) isolates found to carry LRV1, 96 were successfully genotyped. Patient clinical data were linked to the LRV data.
The rate of treatment failure for LRV1-positive isolates was 37% (15/41) versus 40% (2/5) among LRV1-negative isolates (p 0.88). Concerning LRV1 genotypes, two predominant LRV1 groups emerged, groups A (23% (22/96)) and B (70% (67/96)). The treatment failure rate was 37% (3/8) for group A and 45% (9/20) for group B (p 0.31).
Neither the presence nor genotype of LRV1 in patients with L. guyanensis seemed to correlate with pentamidine treatment failure. |
| doi_str_mv | 10.1016/j.cmi.2020.04.037 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02569704v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1198743X20302652</els_id><sourcerecordid>2400551003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-4d7f6b9b9f9974c0d7407ec350d9dbcace1f07c9d3ff66f662a6591c02f677a13</originalsourceid><addsrcrecordid>eNp9kMtqHDEQRUWI8Sv-gGxCL-NFt0uPlkZkZYwfgYEskkB2QiOVYg39cCT1gP8-GsaZZaBARencuziEfKTQUaDyZtu5MXYMGHQgOuDqHTmnQuoWpKbv6071qlWC_zojFzlvAYBxLk7JGWd8BWwlz8n3Ncb8PNop2l1MS25-44QlusbHHaYcy2sTczPNpUk42IK-KXMzHDO5fpaEtow4lSbYOCwJP5CTYIeMV2_vJfn5cP_j7qldf3v8ene7bp3gUFrhVZAbvdFBayUceCVAoeM9eO03zjqkAZTTnocgZR1mZa-pAxakUpbyS3J96H22g3lJcbTp1cw2mqfbtdnfgPVSKxC7Pfv5wL6k-c-CuZgxZofDYCecl2yYAOh7CsArSg-oS3POCcOxm4LZezdbU72bvXcDwlTvNfPprX7ZjOiPiX-iK_DlAGAVsouYTHYRJ4c-JnTF-Dn-p_4vpm-TqQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2400551003</pqid></control><display><type>article</type><title>Leishmaniavirus genetic diversity is not related to leishmaniasis treatment failure</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Ginouvès, M. ; Couppié, P. ; Simon, S. ; Bourreau, E. ; Rogier, S. ; Brousse, P. ; Travers, P. ; Pommier de Santi, V. ; Demar, M. ; Briolant, S. ; Prévot, G.</creator><creatorcontrib>Ginouvès, M. ; Couppié, P. ; Simon, S. ; Bourreau, E. ; Rogier, S. ; Brousse, P. ; Travers, P. ; Pommier de Santi, V. ; Demar, M. ; Briolant, S. ; Prévot, G.</creatorcontrib><description>The outcome of American tegumentary leishmaniasis (ATL) may depend on the presence of the Leishmania RNA virus (LRV). This virus may be involved in treatment failure. We aimed to determine whether genetic clusters of LRV1 are involved in this therapeutic outcome.
The presence of LRV1 was assessed in 129 Leishmania guyanensis isolates from patients treated with pentamidine in French Guiana. Among the 115 (89%) isolates found to carry LRV1, 96 were successfully genotyped. Patient clinical data were linked to the LRV data.
The rate of treatment failure for LRV1-positive isolates was 37% (15/41) versus 40% (2/5) among LRV1-negative isolates (p 0.88). Concerning LRV1 genotypes, two predominant LRV1 groups emerged, groups A (23% (22/96)) and B (70% (67/96)). The treatment failure rate was 37% (3/8) for group A and 45% (9/20) for group B (p 0.31).
Neither the presence nor genotype of LRV1 in patients with L. guyanensis seemed to correlate with pentamidine treatment failure.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1016/j.cmi.2020.04.037</identifier><identifier>PMID: 32380286</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Bacteriology ; Cardiology and cardiovascular system ; Emerging diseases ; Genotype ; Human health and pathology ; Infectious diseases ; Leishmania guyanensis ; Life Sciences ; LRV1 ; Microbiology and Parasitology ; Parasitology ; Pentamidine ; Treatment failure ; Virology</subject><ispartof>Clinical microbiology and infection, 2021-02, Vol.27 (2), p.286.e1-286.e5</ispartof><rights>2020 European Society of Clinical Microbiology and Infectious Diseases</rights><rights>Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-4d7f6b9b9f9974c0d7407ec350d9dbcace1f07c9d3ff66f662a6591c02f677a13</citedby><cites>FETCH-LOGICAL-c430t-4d7f6b9b9f9974c0d7407ec350d9dbcace1f07c9d3ff66f662a6591c02f677a13</cites><orcidid>0000-0002-7268-4953 ; 0000-0002-9219-3764</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32380286$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://amu.hal.science/hal-02569704$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Ginouvès, M.</creatorcontrib><creatorcontrib>Couppié, P.</creatorcontrib><creatorcontrib>Simon, S.</creatorcontrib><creatorcontrib>Bourreau, E.</creatorcontrib><creatorcontrib>Rogier, S.</creatorcontrib><creatorcontrib>Brousse, P.</creatorcontrib><creatorcontrib>Travers, P.</creatorcontrib><creatorcontrib>Pommier de Santi, V.</creatorcontrib><creatorcontrib>Demar, M.</creatorcontrib><creatorcontrib>Briolant, S.</creatorcontrib><creatorcontrib>Prévot, G.</creatorcontrib><title>Leishmaniavirus genetic diversity is not related to leishmaniasis treatment failure</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>The outcome of American tegumentary leishmaniasis (ATL) may depend on the presence of the Leishmania RNA virus (LRV). This virus may be involved in treatment failure. We aimed to determine whether genetic clusters of LRV1 are involved in this therapeutic outcome.
The presence of LRV1 was assessed in 129 Leishmania guyanensis isolates from patients treated with pentamidine in French Guiana. Among the 115 (89%) isolates found to carry LRV1, 96 were successfully genotyped. Patient clinical data were linked to the LRV data.
The rate of treatment failure for LRV1-positive isolates was 37% (15/41) versus 40% (2/5) among LRV1-negative isolates (p 0.88). Concerning LRV1 genotypes, two predominant LRV1 groups emerged, groups A (23% (22/96)) and B (70% (67/96)). The treatment failure rate was 37% (3/8) for group A and 45% (9/20) for group B (p 0.31).
Neither the presence nor genotype of LRV1 in patients with L. guyanensis seemed to correlate with pentamidine treatment failure.</description><subject>Bacteriology</subject><subject>Cardiology and cardiovascular system</subject><subject>Emerging diseases</subject><subject>Genotype</subject><subject>Human health and pathology</subject><subject>Infectious diseases</subject><subject>Leishmania guyanensis</subject><subject>Life Sciences</subject><subject>LRV1</subject><subject>Microbiology and Parasitology</subject><subject>Parasitology</subject><subject>Pentamidine</subject><subject>Treatment failure</subject><subject>Virology</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMtqHDEQRUWI8Sv-gGxCL-NFt0uPlkZkZYwfgYEskkB2QiOVYg39cCT1gP8-GsaZZaBARencuziEfKTQUaDyZtu5MXYMGHQgOuDqHTmnQuoWpKbv6071qlWC_zojFzlvAYBxLk7JGWd8BWwlz8n3Ncb8PNop2l1MS25-44QlusbHHaYcy2sTczPNpUk42IK-KXMzHDO5fpaEtow4lSbYOCwJP5CTYIeMV2_vJfn5cP_j7qldf3v8ene7bp3gUFrhVZAbvdFBayUceCVAoeM9eO03zjqkAZTTnocgZR1mZa-pAxakUpbyS3J96H22g3lJcbTp1cw2mqfbtdnfgPVSKxC7Pfv5wL6k-c-CuZgxZofDYCecl2yYAOh7CsArSg-oS3POCcOxm4LZezdbU72bvXcDwlTvNfPprX7ZjOiPiX-iK_DlAGAVsouYTHYRJ4c-JnTF-Dn-p_4vpm-TqQ</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Ginouvès, M.</creator><creator>Couppié, P.</creator><creator>Simon, S.</creator><creator>Bourreau, E.</creator><creator>Rogier, S.</creator><creator>Brousse, P.</creator><creator>Travers, P.</creator><creator>Pommier de Santi, V.</creator><creator>Demar, M.</creator><creator>Briolant, S.</creator><creator>Prévot, G.</creator><general>Elsevier Ltd</general><general>Elsevier for the European Society of Clinical Microbiology and Infectious Diseases</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-7268-4953</orcidid><orcidid>https://orcid.org/0000-0002-9219-3764</orcidid></search><sort><creationdate>20210201</creationdate><title>Leishmaniavirus genetic diversity is not related to leishmaniasis treatment failure</title><author>Ginouvès, M. ; Couppié, P. ; Simon, S. ; Bourreau, E. ; Rogier, S. ; Brousse, P. ; Travers, P. ; Pommier de Santi, V. ; Demar, M. ; Briolant, S. ; Prévot, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-4d7f6b9b9f9974c0d7407ec350d9dbcace1f07c9d3ff66f662a6591c02f677a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bacteriology</topic><topic>Cardiology and cardiovascular system</topic><topic>Emerging diseases</topic><topic>Genotype</topic><topic>Human health and pathology</topic><topic>Infectious diseases</topic><topic>Leishmania guyanensis</topic><topic>Life Sciences</topic><topic>LRV1</topic><topic>Microbiology and Parasitology</topic><topic>Parasitology</topic><topic>Pentamidine</topic><topic>Treatment failure</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ginouvès, M.</creatorcontrib><creatorcontrib>Couppié, P.</creatorcontrib><creatorcontrib>Simon, S.</creatorcontrib><creatorcontrib>Bourreau, E.</creatorcontrib><creatorcontrib>Rogier, S.</creatorcontrib><creatorcontrib>Brousse, P.</creatorcontrib><creatorcontrib>Travers, P.</creatorcontrib><creatorcontrib>Pommier de Santi, V.</creatorcontrib><creatorcontrib>Demar, M.</creatorcontrib><creatorcontrib>Briolant, S.</creatorcontrib><creatorcontrib>Prévot, G.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ginouvès, M.</au><au>Couppié, P.</au><au>Simon, S.</au><au>Bourreau, E.</au><au>Rogier, S.</au><au>Brousse, P.</au><au>Travers, P.</au><au>Pommier de Santi, V.</au><au>Demar, M.</au><au>Briolant, S.</au><au>Prévot, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Leishmaniavirus genetic diversity is not related to leishmaniasis treatment failure</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>27</volume><issue>2</issue><spage>286.e1</spage><epage>286.e5</epage><pages>286.e1-286.e5</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>The outcome of American tegumentary leishmaniasis (ATL) may depend on the presence of the Leishmania RNA virus (LRV). This virus may be involved in treatment failure. We aimed to determine whether genetic clusters of LRV1 are involved in this therapeutic outcome.
The presence of LRV1 was assessed in 129 Leishmania guyanensis isolates from patients treated with pentamidine in French Guiana. Among the 115 (89%) isolates found to carry LRV1, 96 were successfully genotyped. Patient clinical data were linked to the LRV data.
The rate of treatment failure for LRV1-positive isolates was 37% (15/41) versus 40% (2/5) among LRV1-negative isolates (p 0.88). Concerning LRV1 genotypes, two predominant LRV1 groups emerged, groups A (23% (22/96)) and B (70% (67/96)). The treatment failure rate was 37% (3/8) for group A and 45% (9/20) for group B (p 0.31).
Neither the presence nor genotype of LRV1 in patients with L. guyanensis seemed to correlate with pentamidine treatment failure.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32380286</pmid><doi>10.1016/j.cmi.2020.04.037</doi><orcidid>https://orcid.org/0000-0002-7268-4953</orcidid><orcidid>https://orcid.org/0000-0002-9219-3764</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1198-743X |
| ispartof | Clinical microbiology and infection, 2021-02, Vol.27 (2), p.286.e1-286.e5 |
| issn | 1198-743X 1469-0691 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02569704v1 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Bacteriology Cardiology and cardiovascular system Emerging diseases Genotype Human health and pathology Infectious diseases Leishmania guyanensis Life Sciences LRV1 Microbiology and Parasitology Parasitology Pentamidine Treatment failure Virology |
| title | Leishmaniavirus genetic diversity is not related to leishmaniasis treatment failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A06%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Leishmaniavirus%20genetic%20diversity%20is%20not%20related%20to%20leishmaniasis%20treatment%20failure&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Ginouv%C3%A8s,%20M.&rft.date=2021-02-01&rft.volume=27&rft.issue=2&rft.spage=286.e1&rft.epage=286.e5&rft.pages=286.e1-286.e5&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1016/j.cmi.2020.04.037&rft_dat=%3Cproquest_hal_p%3E2400551003%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2400551003&rft_id=info:pmid/32380286&rft_els_id=S1198743X20302652&rfr_iscdi=true |